Werewolf Therapeutics (NASDAQ:HOWL) Stock Rating Raised to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Werewolf Therapeutics (NASDAQ:HOWL) from a hold rating to a strong-buy rating in a report released on Monday,Zacks reports.

Other equities analysts have also issued reports about the stock. Weiss Ratings upgraded shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Wall Street Zen upgraded Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $4.00.

Werewolf Therapeutics Trading Down 0.9%

Shares of HOWL stock opened at $0.92 on Monday. Werewolf Therapeutics has a 12 month low of $0.27 and a 12 month high of $2.13. The stock has a market cap of $44.81 million, a PE ratio of -1.21 and a beta of 0.51. The company’s fifty day moving average price is $0.76 and its 200-day moving average price is $0.64.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.36. The business had revenue of $21.00 million during the quarter, compared to the consensus estimate of $21.00 million. On average, sell-side analysts forecast that Werewolf Therapeutics will post -0.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Squarepoint Ops LLC bought a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $37,000. Bank of America Corp DE bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $112,000. Finally, BlackRock Inc. purchased a new position in shares of Werewolf Therapeutics in the second quarter worth $37,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing investigational cancer immunotherapies. The company’s programs are designed to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues, with the goal of improving the effectiveness and tolerability of immune-based treatments.

Werewolf’s research is based on its proprietary INDUKINE platform, which uses molecular masking and tumor-activated mechanisms to conditionally regulate immune-stimulating proteins.